More Patients with Lung Cancer Could Benefit from Immunotherapy, Study Shows
SINGAPORE and LUGANO, Switzerland, Dec. 21, 2015
SINGAPORE and LUGANO, Switzerland, Dec. 21, 2015 /PRNewswire/ —
KEYNOTE-010 data further supports broadening pembrolizumab availability for all advanced NSCLC patients with PD-L1 expression over 1%
TRADITIONAL CHINESE FULL TEXT http://www.esmo.org/content/download/73096/1302137/TRAD_CHIN_PR_LBA3_Lung_Keynote010.pdf
SIMPLE CHINESE FULL TEXT http://www.esmo.org/content/download/73095/1302131/SIMP_CHIN_PR_LBA3_Lung_Keynote010.pdf
More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore (1), in conjunction with a publication in The Lancet (2).
The study shows that two doses of the anti-PD-1 antibody pembrolizumab, the US Food and Drug Administration (FDA)-approved 2 mg/kg dose and an investigational 10 mg/kg dose, each given every 3 weeks, improve median survival in all PD-L1-positive patients compared with the commonly used chemotherapeutic agent docetaxel. The benefit is even greater in the group of patients with PD-L1 staining in ≥50% of tumour cells.
The open-label KEYNOTE-010 is the first study to assess the benefits of immunotherapy as second- or later line in patients with refractory lung cancer selected for PD-L1 expression. From August 2013 to April 2015, 1034 patients with advanced NSCLC from 24 countries/regions (EU nations, US and Asia, including Japan, South Korea and Taiwan) were randomised to pembrolizumab (2 mg/kg or 10 mg/kg) or docetaxel. All patients had experienced disease progression after platinum-containing systemic therapy and were stratified by PD-L1 expression level (tumour proportion score, TPS ≥50% vs 1-49%).
For media RSVPs or enquiries, please contact:
Ruder Finn Asia Petrina Loh Account Executive DID: +6563367694 / Mobile: +6590052790 firstname.lastname@example.org
Ruder Finn Asia Michelle Tan Account Executive DID: +6563366408 / Mobile: +6591864848 email@example.com
ESMO Press Office firstname.lastname@example.org